Vyjuvek for DEB Earns Orphan Drug Designation in Japan
source: pixabay.com

Vyjuvek for DEB Earns Orphan Drug Designation in Japan

Healio Psoriatic Disease recently reported that Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy designed for people with dystrophic epidermolysis bullosa (DEB), was granted Orphan Drug designation (ODD) by the Japanese…

Continue Reading Vyjuvek for DEB Earns Orphan Drug Designation in Japan
Congressman George Santos Apparently Lied About Helping Kids Living with Epidermolysis Bullosa
source: unsplash.com

Congressman George Santos Apparently Lied About Helping Kids Living with Epidermolysis Bullosa

According to a story from VICE News, Congressman George Santos was recently elected to Congress in the 2022 mid-term elections. Since then, his past has been placed under scrutiny, and…

Continue Reading Congressman George Santos Apparently Lied About Helping Kids Living with Epidermolysis Bullosa

Raising Awareness of Recessive Dystrophic Epidermolysis Bullosa: Patterson’s Story (Pt. 2)

Before you read on, make sure to check out Part 1 of our interview, where Annie, Peter, and Patterson discuss what recessive dystrophic epidermolysis bullosa (RDEB) is, Patterson's diagnostic journey, and how…

Continue Reading Raising Awareness of Recessive Dystrophic Epidermolysis Bullosa: Patterson’s Story (Pt. 2)
Study Shares Calcipotriol Benefits for Dystrophic Epidermolysis Bullosa
jniittymaa0 / Pixabay

Study Shares Calcipotriol Benefits for Dystrophic Epidermolysis Bullosa

People with epidermolysis bullosa (EB) often experience symptoms such as intense itching or severe pain. Unfortunately, these symptoms can be debilitating and may greatly affect overall quality-of-life. However, some burgeoning…

Continue Reading Study Shares Calcipotriol Benefits for Dystrophic Epidermolysis Bullosa

Two Epidermolysis Bullosa Nonprofits United to Make the Largest Global Organization for EB

EB Research Partnership (EBRP) is based out of New York, United States. EB Research Foundation (EBRF) is an organization based out of Australia with the same goals. The two organizations  have…

Continue Reading Two Epidermolysis Bullosa Nonprofits United to Make the Largest Global Organization for EB
Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval
source: pixabay.com

Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval

According to a story from prnewswire.com, the biopharmaceutical company InMed Pharmaceuticals, Inc. has recently announced that that company's Clinical Trial Application has been approved in the Netherlands. This approval will…

Continue Reading Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval
With Clinical Hold Lifted, Abeona Moves Forward with Recessive Dystrophic Epidermolysis Bullosa Trial
source: pixabay.com

With Clinical Hold Lifted, Abeona Moves Forward with Recessive Dystrophic Epidermolysis Bullosa Trial

According to a story from Benzinga, the drug company Abeona Therapeutics, Inc. has recently announced plans to move forward with its phase 3 clinical trial following the lifting of the…

Continue Reading With Clinical Hold Lifted, Abeona Moves Forward with Recessive Dystrophic Epidermolysis Bullosa Trial